NAJMUDDIN KARIMJEE: Open Payments
NPI 1285660241 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,749 in 101 payments from 17 companies in 2025. Trend: 2023 $1,183 · 2024 $2,132 · 2025 $1,749
Food & beverage: $1,749
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $638 |
| Astellas Pharma US Inc | 13 | $258 |
| AstraZeneca Pharmaceuticals LP | 6 | $160 |
| Exact Sciences Corporation | 3 | $154 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $101 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Mannkind Corporation | 3 | $52 |
| Amgen Inc. | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $45 |
Products named: Veozah, UBRELVY, SYNTHROID, The Cologuard Plus Collection Kit, FARXIGA, VRAYLAR, QULIPTA, CAPLYTA.
Industry payments across TX — which companies pay providers there.
